- Active, not recruiting
NCT01863550: Phase 3 - Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in NDMM
Updated: Sep 7, 2022
ENDURANCE TRIAL - ECOG-E1A11
(the ENDURANCE trial; E1A11)
KRd
VRd
Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma
This randomized phase III trial studies bortezomib, lenalidomide, and dexamethasone to see how well they work compared to carfilzomib, lenalidomide, and dexamethasone in treating patients with newly diagnosed multiple myeloma. Bortezomib and carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Lenalidomide may help the immune system kill abnormal blood cells or cancer cells. Drugs used in chemotherapy, such as dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether bortezomib, lenalidomide, and dexamethasone are more or less effective than carfilzomib, lenalidomide, and dexamethasone in treating patients with multiple myeloma
Sponsor
ECOG-ACRIN Cancer Research Group
Collaborator
National Cancer Institute (NCI)
Multiple Locations
ClinicalTrials.gov Identifier: NCT01863550
Official Title: Randomized Phase III Trial of Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide, and Dexamethasone (CRd) Followed by Limited or Indefinite Duration Lenalidomide Maintenance in Patients With Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)
First Posted : May 29, 2013
Click here for details on ClinicalTrials.gov
Carfilzomib : National Cancer Institute
Carfilzomib : MedlinePlus Drug Information
Bortezomib : National Cancer Institute
Bortezomib : MedlinePlus Drug Information
Lenalidomide: National Cancer Institute
Lenalidomide: MedlinePlus Drug Information
Dexamethasone : National Cancer Institute
Dexamethasone : MedlinePlus Drug Information
Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial
Lancet Oncol; 2020 Oct
1655 Carfilzomib 56mg/m2 Twice-Weekly in Combination with Dexamethasone and Daratumumab (KdD) Versus Daratumumab in Combination with 8 Cycles of Bortezomib and Dexamethasone (DVd); A Matching-Adjusted Indirect Treatment Comparison
Program: Oral and Poster Abstracts
Session: 905. Outcomes Research—Malignant Conditions (Lymphoid Disease): Poster I
Hematology Disease Topics & Pathways:
Diseases, Combinations, Lymphoid Malignancies
Saturday, December 5, 2020, 7:00 AM-3:30 PM
467 Impact of Chromosome 1 Abnormalities Among Patients with Newly Diagnosed Multiple Myeloma: A Subgroup Analysis from the Endurance (ECOG-ACRIN E1A11) Trial
Program: Oral and Poster Abstracts
Type: Oral
Session: 653. Myeloma and Plasma Cell Dyscrasias: Clinical-Prospective Therapeutic Trials; treatment of NDMM and amyloidosis patients
Hematology Disease Topics & Pathways:
Clinical Trials, Adults, Clinical Research, Plasma Cell Disorders, Clinically Relevant, Diseases, Lymphoid Malignancies, Study Population
Sunday, December 12, 2021: 1:00 PM
Drug: Bortezomib
Drug: Carfilzomib
Drug: Dexamethasone
Other: Laboratory Biomarker Analysis
Drug: Lenalidomide
Other: Quality-of-Life Assessment
Location
United States, Alaska
United States, Arizona
United States, Arkansas
United States, California
United States, Colorado
United States, Connecticut
United States, Delaware
United States, District of Columbia
United States, Florida
United States, Georgia
United States, Hawaii
United States, Idaho
United States, Illinois
United States, Indiana
United States, Iowa
United States, Kansas
United States, Kentucky
United States, Louisiana
United States, Maine
United States, Maryland
United States, Massachusetts
United States, Michigan
United States, Minnesota
United States, Missouri
United States, Montana
United States, Nebraska
United States, Nevada
United States, New Hampshire
United States, New Jersey
United States, New Mexico
United States, New York
United States, North Carolina
United States, North Dakota
United States, Ohio
United States, Oklahoma
United States, Oregon
United States, Pennsylvania
United States, South Carolina
United States, South Dakota
United States, Tennessee
United States, Texas
United States, Vermont
United States, Virginia
United States, Washington
United States, West Virginia
United States, Wisconsin
United States, Wyoming
Puerto Rico